Developing Accessible Monoclonal Antibodies to Treat COVID-19 with Vu Truong Aridis Pharmaceuticals

Vu Truong, CEO, Aridis Pharmaceuticals is taking on the challenge of making an inhaled monoclonal antibody to treat COVID-19 to allow for the easier patient access.  Drawing on their work in infectious diseases and with a number of monoclonal antibodies candidates to treat bacteria infection associated with superbugs and antibiotic resistance, Aridis is  finding ways to overcome lack of usage of similar potent antibodies from Regeneron and Eli Lilly to combat the coronavirus.

@Aridis_Pharma #AridisPharma #Aridis #Superbugs #AMR #InfectiousDisease #COVID19 #mAb #MonoclonalAntibody #immunotherapy #RespiratoryInfections #CoronavirusVariants

Download the transcript here

Share on facebook
Share on twitter
Share on linkedin
Related Post


Sign up for Breaking News, Newsletter, Blog Posts and Special Deals from 1631 Digital and their media/marketing partners.

Subscribers agree to be contacted from 1631 Digital News and/or their media/marketing partners for breaking news alerts, newsletters and special media marketing offers via email, mail and/or texting communication.